On November 10, 2026, gastrointestinal oncology guidelines incorporated Tevimbra® (Tislelizumab 100 mg/10 mL injection) developed by BeiGene as a premier anti-PD-1 humanized monoclonal antibody for unresectable or metastatic esophageal squamous cell carcinoma (ESCC).

Distinguished by innovative Fc-engineering that minimizes macrophage-mediated antibody-dependent cellular phagocytosis (ADCP), Tevimbra circumvents a major mechanism of secondary immunotherapy resistance, yielding superior survival outcomes in advanced esophageal cancers.

Through Critical Kare Pharma, certified authentic manufacturer vials of Tevimbra Tislelizumab 100mg Injection are delivered to oncology clinics worldwide under strict 2°C–8°C validated logistics.

The RATIONALE-302 & RATIONALE-306 Trials

• RATIONALE-302 (Second-Line ESCC): Tislelizumab monotherapy demonstrated statistically significant overall survival prolongation over chemotherapy (median 8.6 vs 6.3 months; HR 0.70, p = 0.0001), with a confirmed ORR of 20.3% vs 9.8%.
• RATIONALE-306 (First-Line ESCC): When combined with platinum-fluoropyrimidine chemotherapy, tislelizumab extended median overall survival to 17.2 months versus 10.6 months with chemotherapy alone across all PD-L1 expression subgroups.

Fc-Engineered Pharmacology

Classic IgG4 anti-PD-1 antibodies can bind Fc gamma receptors (FcγRs) on macrophages, paradoxically causing macrophages to clear and destroy tumor-infiltrating PD-1+ CD8+ T-cells. Tislelizumab features a specially engineered Fc region that eliminates FcγR binding, preserving T-cell viability and sustaining prolonged tumor lysis.

Administration & Named-Patient Supply

Administered as 200 mg IV infusion every 3 weeks. Sourced directly through Critical Kare Pharma under official national named-patient and compassionate use frameworks across the Middle East, Latin America, Europe, and Asia.